calciol/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases expanded Disability Status Scale (EDSS)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Average progression of the EDSS score was significantly lower in the cholecalciferol group (−0.06 ± 0.78) compared with the placebo group (0.32 ± 0.87, 95% CI −0.614 to −0.043; p = 0.03).”
Quoted verbatim from Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE).. - Study
- RCT
- Duration
- 22 months
- Dose
- 100,000 IU oral solution every other week (equivalent to 7,143 IU/day) for 96 weeks
- Population
- Completers' population only (patients who finished the 96-week trial, 45 per arm) with relapsing-remitting MS, low serum 25OHD, all on interferon beta-1a background in both arms; not the intention-to-treat population
Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE).2019PMID:31454777An author is affiliated with a producerPermalink
Keep reading
- Everything the graph holds on calciol
- Every compound studied against Expanded Disability Status Scale (EDSS)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PT91V83DY4TBWB9Y47JGKG